Whitehawk Therapeutics Inc (NASDAQ: WHWK) is a clinical-stage biopharmaceutical company that develops and, until recently, commercialized oncology drug products. Revenue was generated through direct product sales of FYARRO, an approved treatment for advanced malignant PEComa, distributed through specialty distributors and a specialty pharmacy. FYARRO generated net product sales of $26.0 million in FY2024 and $7.1 million in FY2025, before Whitehawk divested the asset on March 25, 2025, after which the company no longer commercializes FYARRO. Following the divestiture, Whitehawk received $101.3 million in proceeds (FY2025 investing activities) and raised $100.0 million in gross proceeds from a common stock and pre-funded warrant sale. The company reported a net loss of $63.7 million and cash used in operating activities of $59.6 million for FY2024. David J. Lennon, Ph.D. serves as Chief Executive Officer and President, as of the filing date of March 12, 2026.

Revenue model

Product sales of FDA-approved FYARRO through specialty distributors and a specialty pharmacy, subject to gross-to-net adjustments including Medicaid Drug Rebate Program rebates, TRICARE rebates, and limited product returns. FYARRO was divested on March 25, 2025; no commercial product revenue stream exists as of the filing date.

Products and services

FYARRO: an approved therapy for advanced malignant PEComa, commercially launched February 22, 2022, and divested March 25, 2025. Pipeline product candidates in development are referenced but not named in the provided excerpts.

Customers and end markets

Specialty distributors and a specialty pharmacy serving patients with advanced malignant PEComa. Reimbursement flows through Medicaid, TRICARE, and commercial insurers.

Value-chain role

Drug developer and former commercial-stage specialty pharmaceutical company. Distribution executed through specialty distributors and a specialty pharmacy under individual distribution agreements. Manufacturing outsourced to third-party manufacturers.

Geographic exposure

Primary operations in the United States. Regulatory references include EU GDPR and UK GDPR compliance obligations, indicating some international operational exposure, though no international revenue is specified in the excerpts.

Source: SEC 10-K, filed 2026-03-12

Industry: Pharmaceutical Preparations Peers: 4D Molecular Therapeutics Inc AVEO PHARMACEUTICALS, INC. Vaxart Inc Bioatla Inc Generation Bio Co. Outlook Therapeutics Inc Poseida Therapeutics, Inc. Vaxxinity, Inc.